In cases of recurrence after quizartinib treatment in patients with FLT3-ITD-positive AML, secondary mutations at D835 and Y842 residues as well as at the commonly known “gatekeeper residue” F691 in the kinase domain have been reported (Figure 1) [96]. Here, FLT3 is linked to acute myeloid leukemia.